Assyro AI
510(k) Predicate Database
FDA 510(k) ClearanceGEX

Moses™ 200 D/F/L Laser Fiber (M0068130100); Moses™ 365 D/F/L Laser Fiber (M0068130110); Moses™ 550 D/F/L Laser Fiber (M0068130120)

FDA 510(k) K252529 · Boston Scientific Corporation

510(k) number
K252529
Device name
Moses™ 200 D/F/L Laser Fiber (M0068130100); Moses™ 365 D/F/L Laser Fiber (M0068130110); Moses™ 550 D/F/L Laser Fiber (M0068130120)
Applicant
Boston Scientific Corporation
Product code
GEX
Decision
Substantially Equivalent
Decision date
2025-10-30
Device class
Class 2
Regulation number
878.4810
Advisory committee
General, Plastic Surgery
Medical specialty
General, Plastic Surgery

Candidate predicate devices

Other devices cleared under product code GEX — the same regulatory device type, and therefore candidate predicates for a substantial-equivalence comparison. Confirm each predicate is legally marketed before relying on it.

510(k)DeviceApplicantDecision date
K260690LumiGlam Laser System (SHE-LSP601-3)Beijing Sano Laser S&T Development Co.,Ltd2026-06-04
K260489LASEmaR 1500Eufoton S.R.L.2026-05-29
K260138LUNE PureHygieneEnamel Pure2026-05-29
K253245Boston 2910 (Boston 2910)Boston Aesthetics, Inc.2026-05-21
K260100MOSES Raydar™Boston Scientific Corporation2026-05-18
K261214PICO SHINING (PICO-K; PICOFY)Speclipse, Inc.2026-05-11
K260974CO2 Laser Machine (Monica-I,Monica-II)Nanjing Bestview Laser S&T Co., Ltd.2026-05-07
K253251Leaseir MHR Xcell (console) (MHR-100b); Handpiece: Dual (810-b and Blend-b); Handpiece: Quad (810-b and Blend-b)Leaseir Technologies, Slu2026-05-04
K260256Q-Switched Nd: YAG Laser SystemsShanghai Apolo Medical Technology Co., Ltd.2026-05-04
K261094YellowStarAsclepion Laser Technologies GmbH2026-04-29
K253765VANISH PRODdc Technologies, Inc.2026-04-22
K260153Q-Switched Nd: YAG Laser System (Glamor Q)Nanjing Bestview Laser S&T Co., Ltd.2026-04-20

Building a 510(k) around this device type?

Assyro turns predicate research into a substantial-equivalence comparison and an eSTAR-ready 510(k) workflow — so predicate strategy, testing evidence, and labeling stay aligned before FDA review.